Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xilio Therapeutics (XLO) Invested Capital (2024 - 2025)

Historic Invested Capital for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to -$8.1 million.

  • Xilio Therapeutics' Invested Capital fell 13859.54% to -$8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.1 million, marking a year-over-year decrease of 13859.54%. This contributed to the annual value of $17.6 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Xilio Therapeutics' Invested Capital stood at -$8.1 million, which was down 13859.54% from $7.1 million recorded in Q2 2025.
  • In the past 5 years, Xilio Therapeutics' Invested Capital registered a high of $33.4 million during Q2 2024, and its lowest value of -$8.1 million during Q3 2025.